Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus human herpesvirus-8
Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus human herpesvirus-8
复制标题
DOI：
10.1182/blood.v90.3.1186
复制
发表时间：
1997-08-01
期刊：
影响因子：
20.3
通讯作者：
Cesarman, E
中科院分区：
文献类型：
--
作者：
Horenstein, MG;Nador, RG;Cesarman, E
原发性积液性（体腔基础）淋巴瘤（PEL）是最近发现的一种恶性淋巴瘤亚型，具有独特的临床和生物学特征，最显著的是其通常感染卡波西肉瘤相关疱疹病毒（KSHV）。绝大多数病例还含有eb病毒（EBV）。这种双重病毒感染是人类肿瘤中一致的双重疱疹病毒感染的第一个例子，并为研究病毒相互作用提供了独特的模型。我们分析了EBV潜伏性基因表达的模式来确定该代理的致病作用在象素,我们检查了五象素合并感染EBV和KSHV逆转录-聚合酶链反应(rt - pcr)、原位杂交、免疫组织化学,EBER1 mRNA,一致的病毒潜伏期的标志,在所有图像的基本单位是积极的情况下,虽然比non-PEL控制在较低水平由于EBER1表达式只有一个变量的子集淋巴瘤细胞。所有PEL病例中，仅编码EBNA1且具有潜伏期I和潜伏期II特征的op -启动mRNA呈阳性，而编码所有ebna且具有潜伏期III特征的Wp-和cp -启动mRNA在所有病例中均呈阴性。LMP1 mRNA以潜伏期II和潜伏期III表达，存在于3例PEL中，尽管其水平非常低，免疫组织化学无法在蛋白质水平检测到。所有病例均检测到低水平的LMP2A mRNA。BZLF1是一种早中期裂解期标记物，在4例病例中呈弱阳性，提示极少量细胞发生了多产性病毒感染，斑马抗原表达证实了这一点。因此，PELs表现出受限的潜伏期模式，所有病例均表达EBNA1， LMP1和LMP2A水平较低。(C) 1997年由美国血液病学会出版。
Primary effusion (body cavity-based) lymphoma (PEL) is a recently recognized subtype of malignant lymphoma that exhibits distinctive clinical and biological features, most notably its usual infection with the Kaposi's sarcoma-associated herpesvirus (KSHV). The vast majority of cases also contain Epstein-Barr virus (EBV). This dual viral infection is the first example of a consistent dual herpesviral infection in a human neoplasm and provides a unique model to study viral interactions. We analyzed the pattern of EBV latent gene expression to determine the pathogenic role of this agent in PELs, We examined five PELs coinfected with EBV and KSHV by reverse transcription-polymerase chain reaction (RT-PCR), in situ hybridization, and immunohistochemistry, EBER1 mRNA, a consistent marker of viral latency, was positive in all PEL cases, although at lower levels than in the non-PEL controls due to EBER1 expression by only a variable subset of lymphoma cells. Op-initiated mRNA, encoding only EBNA1 and characteristic of latencies I and II, was positive in all PEL cases, Wp- and Cp-initiated mRNAs, encoding all EBNAs and characteristic of latency III, were negative in all cases. LMP1 mRNA, expressed in latencies II and III, was present in three cases of PEL, although at very low levels that were not detectable at the protein level by immunohistochemistry. Low levels of LMP2A mRNA were detected in all cases. BZLF1, an early-intermediate lytic phase marker, was weakly positive in four cases, suggesting a productive viral infection in a very small proportion of cells, which was confirmed by ZEBRA antigen expression. Therefore, PELs exhibit a restricted latency pattern, with expression of EBNA1 in all cases, and low LMP1 and LMP2A levels. (C) 1997 by The American Society of Hematology.